NASDAQ:PPBT Purple Biotech (PPBT) Stock Price, News & Analysis $4.13 -0.68 (-14.14%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Purple Biotech Stock (NASDAQ:PPBT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Purple Biotech alerts:Sign Up Key Stats Today's Range$3.76▼$4.8650-Day Range N/A52-Week Range$3.76▼$36.00Volume123,050 shsAverage Volume14,113 shsMarket Capitalization$104.23 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Purple Biotech Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScorePPBT MarketRank™: Purple Biotech scored higher than 47% of companies evaluated by MarketBeat, and ranked 615th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPurple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePurple Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Purple Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Purple Biotech is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Purple Biotech is -5.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPurple Biotech has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Purple Biotech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.22% of the float of Purple Biotech has been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently decreased by 95.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPurple Biotech does not currently pay a dividend.Dividend GrowthPurple Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.22% of the float of Purple Biotech has been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently decreased by 95.30%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Purple Biotech this week, compared to 1 article on an average week.Search Interest1 people have searched for PPBT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Purple Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Purple Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Purple Biotech is held by insiders.Percentage Held by InstitutionsOnly 9.64% of the stock of Purple Biotech is held by institutions.Read more about Purple Biotech's insider trading history. Receive PPBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PPBT Stock News HeadlinesPurple Biotech (NASDAQ:PPBT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBuy Rating Justified by Promising CM24 Phase 2 Study for Pancreatic Cancer SurvivalSeptember 19, 2024 | markets.businessinsider.comWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.October 8, 2024 | StocksToTrade (Ad)Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24September 18, 2024 | globenewswire.comPurple Biotech Ltd (1YI1.MU)September 17, 2024 | uk.finance.yahoo.com1YI1.SG,0P0001D6KB,0 (1YI1.SG)September 17, 2024 | au.finance.yahoo.comPurple Biotech Ltd (1YI1.DU)September 17, 2024 | sg.finance.yahoo.comPurple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer ResearchSeptember 10, 2024 | markets.businessinsider.comSee More Headlines PPBT Stock Analysis - Frequently Asked Questions How have PPBT shares performed this year? Purple Biotech's stock was trading at $7.3699 at the beginning of the year. Since then, PPBT stock has decreased by 44.0% and is now trading at $4.13. View the best growth stocks for 2024 here. How were Purple Biotech's earnings last quarter? Purple Biotech Ltd (NASDAQ:PPBT) issued its earnings results on Friday, August, 16th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. When did Purple Biotech's stock split? Purple Biotech's stock reverse split before market open on Tuesday, September 17th 2024. The 1-20 reverse split was announced on Friday, September 13th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Purple Biotech? Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/16/2024Today10/08/2024Next Earnings (Estimated)11/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PPBT Previous SymbolNASDAQ:KTOV CUSIPN/A CIK1614744 Webwww.kitovpharma.com Phone(723) 933-3121Fax972-153-39333121Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+142.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.58% Return on Assets-48.06% Debt Debt-to-Equity RatioN/A Current Ratio1.22 Quick Ratio1.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.18 per share Price / Book0.15Miscellaneous Outstanding Shares25,238,000Free Float24,486,000Market Cap$104.23 million OptionableOptionable Beta1.06 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:PPBT) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
